INTRODUCTION:

For a considerable amount of time, harmless commensals known as Candida species have been associated with humans. They are frequently observed on human skin, gastrointestinal, and genitourinary tract mucosal surfaces. However, in patients with impaired immune systems, they transform into opportunistic infections. Because they are opportunistic pathogens, they can lead to systemic infections as well as localized mucosal infections. All major organs are susceptible to colonization and dissemination by Candida species.

Those with significantly compromised immune systems, such as AIDS patients, cancer patients receiving chemotherapy and radiation therapy, and recipients of organ transplants, are particularly vulnerable to systemic infections, which can be fatal. Due to changes in lifestyle and advancements in medical facilities, the number of immunocompromised individuals globally is rising. As a result, infections caused by Over the past 20 years, there has been a significant increase in Candida species, primarily Candida albicans. The effective management of candidiasis has faced a significant and daunting challenge as a result, and costs have multiplied. According to estimates, candidemia-related excess costs in the United States alone range from $1 to $2 billion annually.^1,2 In this section, we summarize various aspects of Candida infections, drug resistance, candidiasis treatment with antifungals, and some preventive measures. In nature, fungi are ubiquitous. There are instances when they are invisible to the unaided eye. Living fungi:

Fig. 1: Outdoors, for example, in soil and on plants.

Fig. 2: On surface and in air

Fig. 3: On Peoples skin and inside body

Though millions of fungus species exist, only a few hundred are known to cause human illness. Fungi include yeasts, molds, and mushrooms, among others. Numerous ailments, such as allergies or asthma, can be brought on by fungi. Find out more about the health risks associated with mold.

· Skin and nail infections or rashes

· Pneumonia, a lung illness that resembles the flu or tuberculosis in symptoms

· Infections with bloodstream

· The meningitis

2. Fungal infection types include:

A. The majority of prevalent fungi infections:

1. Infection of the nail fungus

2. Ringworm

3. Candida vaginalis

4. Oral, throat, and esophageal Candida infection

B. Fungal illnesses specific to residents or visitors to particular regions:

1. Cystomycosis

2. Histoplasmosis

3. Infection with Cryptococcus gatti

C. Fungal infections that impact individuals with compromised immune systems:

1. Aspergillosis

2. Candidiasis

3. Mucormycosis

4. Infection with Candida auris

5. Severe candidiasis

6. The infection caused by Cryptococcus neoformans.

7. Pneumocystis infection

D. Other diseases and health problems caused by fungi:

1. Fungal eye infection

2. Mycetoma

3. Sporotrichosis³

3. Candida Infection:

Thrush is the most frequent name for one of the superficial and localized mucosal diseases caused by Candida species. These infections typically impact the mucosae of the mouth, throat, esophagus, and gastrointestinal tract.

In addition. vulvovaginal candidiasis, or VVC, affects the majority of women at some point in their lives. Recurrent vulvo vaginal candidiasis (RVVC) is the term for the infection that some women have on a regular basis. HIV-positive patients frequently develop oral-pharyngeal candidiasis (OPC), which is thought to be a key indicator of the start of AIDS. Patients with oral cancer and disabled individuals who produce less saliva are also impacted by OPC. But in certain cases, it can result in a major, potentially fatal bloodstream infection that spreads to internal organs and causes a serious health issue known as disseminated candidemia. These individuals often have a mortality rate of between 30% and 50%. Candida infections are the fourth most common cause of hospital acquired infections and rank second in the US. The most prevalent cause of candidemia is Candida albicans; non-albicans strains such as Candida glabrata, Candida tropicalis, Candida parapsilosis, and Candida krusei are the next most common culprits. A little over 16% of bloodstream infections are caused by Candida glabrata, while just 2% of clinical isolates are caused by Candida krusei.^4,5

Due to host processes known as nutritional immunity, which limit microbial access to essential micronutrients like zinc and iron, pathogens frequently experience zinc restriction. Two methods are used by Candida albicans to scavenge ambient zinc. For zinc uptake and development in acidic conditions, the plasma membrane transporter Zrt2 is necessary. Ionic Zn2+ solubility is significantly reduced upon neutralization to pH 7, and thispH rises activation and expression of a second zinc scavenging system, the zincophore.

Fig. 5: Trend of Microbiology

This mechanism is unique to fungi and is made up of a secreted zinc-binding protein called Pra1, which binds zinc and transports it back to the cell through a receptor produced synaptically called Zrt1. Zinc is detoxified through a mechanism that depends on Zrc1 when it is present in excess. Zrc1 is crucial for the production of zincosomes in Candida albicans. Zinc bottlenecks can be low or high in C. albicans in vivo because, in a mouse infection model, Zrt2 and Zrc1 are necessary for kidney and liver colonization, respectively.

4. Antifungal Drugs and their Mechanism of Action:

Numerous antifungal medications have been discovered and are being utilized in clinical settings for the efficient treatment of systemic, fatal fungal diseases and superficial mucosal infections. Even though fungus infections have been recognized for ages, antifungal medications were not developed until the 1930s. Amphotericin B, A medicine from the polyene class that acts as an antifungal was first made available for therapeutic use in 1960. It worked far better than griseofulvin, which was first identified in 1939 as a metabolic byproduct of the mold Penicillium griseofulvum. To this day, amphotericin B is regarded as one of the best antifungals. But in order to combat the escalating problems caused by fungal infections and the rising need for suitable medications, numerous possible antifungal medications have.⁶

Commonly used Antifungal drugs:

1. Azole: flucnazole, Itraconazole, Voriconazle, Posaconazole, Ravuconazole, Isauconazole, Albaconazole, Miconazole, Ketoconazole

2. Polyenes: Amphotericin-B, Nystatin, Micafungin, Anidulafungin

3. Allylamines: Tebinafine, Naftfine,

4. Fluorinated pyrimidine analogs: 5-fluorocytocine

5. The mechanism of action basically divided into five types, such as

a. Azole antifungal drug

b. Polynes

c. Echinocandins

d. Allyamines

e. Fluorinated pyrimidine.^7-13

a. Azole Antifungal Drugs:

Among the most often utilized classes of drugs for treating Candida infections, both systemic and mucosal, is azole-based medication therapy. Since their introduction as antifungals in the 1960s, azole derivatives have been used most rapidly. Azole drugs are categorized as triazoles or imidazole’s based on the presence or absence of two or three nitrogen’s in the five-membered azole ring. Having a wide range of effects on yeast and filamentous fungus, the majority of azole derivatives are fungistatic. The precursors of ergosterol, on the other hand, like Within the cell, lanosterol, 4,14-dimethly zymosterol, and 24-methylene dihydrolanosterol incorporate into the plasma membrane, altering its shape and function. It consequently enhances the cell's ability to absorb drugs and absorb water. The cell's altered plasma membrane structure caused by azole also causes a number of additional reactions, including as the changes to the oxidative and nitrosative stresses, the inhibition of hyphal development, and the deactivation of vacuolar ATPases (V-ATPase).^14,15

Fig. 6: Mechanism of action of azole antifungal drug

Fig. 7: Mechanism of action of polyens antifungal drug

b. Polyenes:

The polyene antibiotics, which are derived from Streptomyces species, are fungicidal in nature rather than fungistatic like azole medicines, and they have a wider spectrum of action than many other antifungal medications. The three polyenes that are most frequently used are natamycin, nystatin, and amphotericin B. These medications work by selectively binding to ergosterol, which is found in the plasma membrane. This compromises the integrity of the cell membrane and causes cell death. According to research by Matsumori et al., amphotericin B interacts directly with ergosterol while very little with its analog, cholesterol, in mammals. Additional data, such as the Compared to sterol-free and cholesterol-containing membranes, amphotericin B has a higher affinity for ergosterol-containing membranes. has also been used to support this intermolecular interaction.^16,17

c. Eschinocandins:

These substances belong to a class of lipoproteins that were found to have both in vivo and in vitro fungicidal activity against Candida in the 1970s. For medicinal uses, caspofungin, micafungin, and anidulafungin are the most often utilized echinocandins. These medications function as selective noncompetitive inhibitors of the membrane heterodimeric protein β-(1,3)-glucan synthase, which is in charge of synthesizing β-glucan. Recent research on chronic candidiasis brought on by Candida albicans has demonstrated that anidulafungin, a semisynthetic echinocandin, is more effective than fluconazole, a drug that is often used. Comparing this echinocandin to fluconazole, it has a more effective worldwide response and removes bloodstream infections more quickly. Furthermore, there have been fewer long-lasting infections reported following this medication's therapy. The fungicidal action of echinocandin (anidulafungin) may be responsible for this intriguing result. greater response in patients than fungistatic fluconzaole; however, this finding is not transferable in addition to the patient's immunological status and other systemic illnesses may influence the effectiveness of the medications used.^18,19

d. Allylamines:

The two allylamines that are most frequently utilized in therapeutic settings are terbinafine and naftifine. Allylamines work against a variety of fungal agents together with other systemic disorders and the patient's immunological state, The early gene ERG1 in the ergosterol biosynthesis pathway encodes the enzyme squalene epoxidase. When further steps in the ergosterol biosynthesis pathway are impeded, allylamine-treated cells have an excess of squalene and a shortage of ergosterol, an essential component of cell membranes. Additionally, research using of isolated squalene epoxidase revealed that allylamines do in fact target this enzyme. Instead of ergosterol depletion per se, the accumulation of squalene leading to the creation of modified plasma may be the source the fungal cell death caused by allylamines. membrane as well as disturbance of the membrane's structure. This causes the membrane's permeability to rise, which causes cell death. Moreover, naftifine's anti-inflammatory qualities have been shown by tests including decreased superoxide generation and polymorphonuclear leukocyte chemotaxis. Despite its strong efficacy in treating fungi and relieving Naftinfine causes inflammatory signs and symptoms, but it also has certain negative effects, like burning or stinging at the application site.^20,21

Fig. 8: Mechanism of Allylamines

e. Flourinated pyrimidine analogue:

First produced in 1957 as an anti-tumor medication, 5-fluorocytosine, often known as 5-FC is a product of cytosine, a crucial part of nucleic acids. However, there is no proof of its effectiveness in treating cancer. Its antifungal action was further investigated, and in 1968 it was utilized to treat fungal infections, particularly those of the candidiasis and cryptococcosis. While 5-fluorouracil (5-FU), a metabolite of flucytosine, is thought to be toxic to fungal cells, flucytosine itself has no antifungal properties. One may wonder why 5-FU, instead of 5-FC, is not given to patients with candidiasis given its hazardous action This is because 5-FC is extremely harmless but 5-FU is dangerous for mammalian cells.. In this instance, the manner in which is quickly debated. Via cytosine permease, Candida species absorb 5-FC, which is quickly transformed into 5-FU once within the cell. There are two ways that this 5-FU can enter the cell and start becoming harmful The enzyme thymidylate synthase, which is necessary for the synthesis of thymidine, may be inhibited by 5-fluorodeoxyuridine monophosphate (5-FdUMP).., is produced via one pathway from 5-FU. Fungal cells cannot proceed with cell division as a result of blocking DNA synthesis. An further method involves the transformation of 5-FU is converted into 5-fluorouridine triphosphate, which is subsequently into 5-fluorouridine monophosphate. After that, RNA incorporates this latter, replacing normal uridine triphosphate.. Consequently, this stops the fungal cell's ability to synthesize proteins (Figure 1). As a result, fungal pathogens are killed off at the site of infection by both mechanisms, which show to be fatal to them.^22,23,24

Fig. 9: Mechanism of fluorinated Pyrimidine Analogue

5)Treatment of Candidiasis with Biomedicine:

Antifungal medications are being utilized to treat both mucosal and invasive Candida infections, but the results have not been satisfying up to this point despite the fact that their quantity is growing quickly. Furthermore, the majority of antifungal medications significantly harm human cells. Therefore, in order to treat the infected individuals, it has become necessary to develop an alternative to the standard treatments. In addition, preventing the start of diseases is preferable to treating them once they have already begun. The same vaccination techniques that are used to treat many other bacterial diseases can be used to treat this. Despite the long-standing controversy around antibody-based protection, a growing body of evidence is supporting its application in both disease prevention and treatment. The growing number of immunocompromised people who are susceptible to the hazardous effects of traditional medications is making this alternate strategy increasingly important. Antibodies against secretory proteins, heat shock protein, peptides, and cell wall polysaccharides have been produced in order to treat Candida infections. It has been discovered that the synthetic glycopeptide vaccine is highly effective in protecting mice from disseminated candidiasis. Additionally, Beta-mannan trisaccharide from the fungal cell wall was mixed with six 14-mer peptides derived from six different proteins, such as phosphoglycerate kinase, fructose-bis-phosphate, and enolase candidiasis. Additionally, when mice are exposed to Candida albicans, antibodies produced against the peptide conjugate-induced beta glucan can shield them, presumably by preventing the proliferation and attachment of fungi to human cells. Mycograb, a human recombinant antibody produced against Hsp90, has been more significant among the antibodies used in the last ten years to both prevent and treat Candida infections. When this antibody was combined with other antifungal medications, the results were very promising. have reported tha Mycograb works in concert with amphotericin B to provide a synergistic action against a variety of Candida species, including C. albicans, C. krusei, and C. tropicalis. In another trial, mycograb and amphotericin B's lipid-associated formulation were used to treat invasive candidiasis, and the results were encouraging.^25-30

CONCLUSION:

As the number of Candida infections is rising, it is widely acknowledged that treating them carefully will lower the likelihood of morbidity and death for individuals with impaired immune systems. In order to effectively control Candida infections, a number of time- and money-efficient measures must be used. Using the insights gathered from the genomes, proteomics, and transcriptomics of Candia and similar species, the first tactic will be to stop the disease from spreading by immunizing or vaccinating those who are susceptible. The second tactic is to immediately and seriously treat Candida infections. Postponing antifungal medication can result in widesprea candidiasis in the body and systemic candidemia, wherein many internal organs get heavily colonized with various strains of the Candida fungus. illnesses. Advanced technologies such as MALDI-TOF-MS,^31,32 PCR, and DNA microarray should take.

REFERENCES:

1. F. C. Odds, Candida and Candidosis, Bailliere Tindall, London, UK, 2nd edition, 1988.

2. M. H. Miceli, J. A. Díaz, and S. A. Lee. Emerging opportunistic yeast infections. The Lancet Infectious Diseases. 2011; 11(2): 142–151.

3. M. A. Pfaller, P. G. Pappas, and J. R. Wingard. Invasive fungal pathogens: current epidemiological trends. Clinical Infectious Diseases, 2006; 43(1): S3–S14.

4. L. S. Wilson, C. M. Reyes, M. Stolpman, J. Speckman, K. Allen, and J. Beney. The direct cost and incidence of systemic fungal infections. Value in Health. 2002; 5(1): 26–34.

5. J. D. Sobel. Vaginitis, The New England Journal of Medicine. 1997; 337(26): 1896– 1903.

6. A. K. Gupta, D. N. Sauder, and N. H. Shear. Antifungal agents: an overview. Part I. Journal of the American Academy of Dermatology. 1994: 30(5): 677–698.

7. M. Borgers. Mechanism of action of antifungal drugs, with special reference to the imidazole derivatives. Reviews of Infectious Diseases. 1980; 2(4): 520–534.

8. H. Van Den Bossche, J. M. Ruysschaert, and F. Defrise-Quertain. The interaction of miconazole and ketoconazole with lipids. Biochemical Pharmacology. 1982; 31(16): 2609–2617.

9. D. J. Sheehan, C. A. Hitchcock, and C. M. Sibley. Current and emerging azole antifungal agents. Clinical Microbiology Reviews. 1999; 12(1): 40–79.

10. D. C. Lamb, D. E. Kelly, M. R. Waterman, M. Stromstedt, D. Rozman, and S. L. Kelly. Characteristics of the heterologously expressed human lanosterol 14α-demethylase (other names: P45014DM, CYP51, P45051) and inhibition of the purified human and Candidaalbicans CYP51 with azole antifungal agents. Yeast. 1999; 15(9); 755–763.

11. C. A. Hitchcock, K. Dickinson, S. B. Brown, E. G. V. Evans, and D. J. Adams. Interaction of azole antifungal antibiotics with cytochrome P-450-dependent 14α-sterol demethylase purified from Candidaalbicans. Biochemical Journal. 266(2): 475–480.

12. R. Courtney, S. Pai, M. Laughlin, J. Lim, and V. Batra. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrobial Agents and Chemotherapy. 2003; 47(9): 2788–2795.

13. A. J. Carrillo-Muñoz, G. Giusiano, P. A. Ezkurra, and G. Quindós. Antifungal agents: mode of action in yeast cells. Revista Espanola de Quimioterapia. 2006; 19(2): 130–139.

14. Y. Q. Zhang, S. Gamarra, G. Garcia-Effron, S. Park, D. S. Perlin, and R. Rao. Requirement for ergosterol in V-ATPase function underlies antifungal activity of azole drugs. PLoS Pathogens. 2010; 6(6): e1000939

15. F. C. Odds, A. Cockayne, J. Hayward, and A. B. Abbott. Effects of imidazole- and triazole- derivative antifungal compounds on the growth and morphological development of Candidaalbicans hyphae. Journal of General Microbiology. 1985; 131(10): 2581–2589.

16. D. M. Arana, C. Nombela, and J. Pla. Fluconazole at subinhibitory concentrations induces the oxidative- and nitrosative-responsive genes TRR1, GRE2 and YHB1, and enhances the resistance of Candidaalbicans to phagocytes. The Journal of Antimicrobial Chemotherapy. 2010; 65(1): 54–62.

17. N. M. Witzke and R. Bittman. Dissociation kinetics and equilibrium binding properties of polyene antibiotic complexes with phosphatidylcholine/sterol vesicles. Biochemistry. 1984; 23(8): 1668–1674.

18. R. Mouri, K. Konoki, N. Matsumori, T. Oishi, and M. Murata. Complex formation of amphotericin B in sterol-containing membranes as evidenced by surface plasmon resonance. Biochemistry. 2008; 47(30): 7807–7815.

19. R. S. Al-Dhaheri and L. J. Douglas. Apoptosis in Candida biofilms exposed to amphotericin B. Journal of Medical Microbiology. 2010; 59(2): 149–157.

20. R. F. Hector. Compounds active against cell walls of medically important fungi. Clinical Microbiology Reviews. 1993; 6(1): 1–21.

21. A. C. Reboli, A. F. Shorr, C. Rotstein et al. Anidulafungin compared with fluconazole for treatment of candidemia and other forms of invasive candidiasis caused by Candida albicans: a multivariate analysis of factors associated with improved outcome. BMC Infectious Diseases. 2011; 11: article 261.

22. N. H. Georgopapadakou and A. Bertasso. Effects of squalene epoxidase inhibitors on Candida albicans. Antimicrobial Agents and Chemotherapy. 1992A; 36(8): 1779–1781

23. K. Gupta, J. E. Ryder, and E. A. Cooper. Naftifine: a review. Journal of Cutaneous Medicine and Surgery. 2008; 12(2): 51–58.

24. R. B. Diasio, J. E. Bennett, and C. E. Myers. Mode of action of 5-fluorocytosine. Biochemical Pharmacology. 1978; 27(5): 703–707.

25. A. Vermes, H. J. Guchelaar, and J. Dankert. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. Journal of Antimicrobial Chemotherapy. 2000; 46(2): 171–179.

26. J. Morschhäuser. Regulation of multidrug resistance in pathogenic fungi. Fungal Genetics and Biology. 2010; 47(2): 94–106,.

27. R. D. Cannon, E. Lamping, A. R. Holmes et al. Efflux-mediated antifungal drug resistance. Clinical Microbiology Reviews. 2009; 22(2): 291–321.

28. R. J. P. Dawson and K. P. Locher. Structure of a bacterial multidrug ABC transporter. Nature. 2006; 443(7108): 180–185.

29. R. J. P. Dawson and K. P. Locher. Structure of the multidrug ABC transporter Sav1866 from Staphylococcus aureus in complex with AMP-PNP. FEBS Letters. 2007; 581(5): 935–938.

30. H. W. Pinkett, A. T. Lee, P. Lum, K. P. Locher, and D. C. Rees. An inward-facing conformation of a putative metal-chelate-type ABC transporter. Science. 2007; 315(5810): 373–377.

31. M. Florent, T. Noël, G. Ruprich-Robert et al. Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae. Antimicrobial Agents and Chemotherapy. 2009; 53(7): 2982–2990.

32. N. Papon, T. Noël, M. Florent et al. Molecular mechanism of flucytosine resistance in Candida lusitaniae: contribution of the FCY2, FCY1, and FUR1 genes to 5-fluorouracil and fluconazole cross-resistance. Antimicrobial Agents and Chemotherapy. 2007; 51(1): 369– 371.

33. A. R. Dodgson, K. J. Dodgson, C. Pujol, M. A. Pfaller, and D. R. Soll. Clade-specific flucytosine resistance is due to a single nucleotide change in the FUR1 gene of Candidaalbicans. Antimicrobial Agents and Chemotherapy. 2004; 48(6): 2223–2227.

Received on 04.04.2024 Revised on 09.07.2024

Accepted on 13.09.2024 Published on 22.10.2024

Available online from October 31, 2024

Asian J. Research Chem. 2024; 17(5):301-306.

DOI: 10.52711/0974-4150.2024.00052

This work is licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 International License. Creative Commons License.